快速发布企业信息
  • 会展标题Global XDC 2024 第三届生物偶联药全球创新峰会
  • 会展时间2024-09-10 至 2024-09-12
  • 会展地点无锡君来洲际酒店
  • 主办方药明合联WuXi XDC、佰傲谷BioValley
  • 参会费用收费(详询) 
  • 会员评分 综合评分:0.0分

Global XDC 2024 第三届生物偶联药全球创新峰会

2.png


由药明合联WuXi XDC和佰傲谷BioValley共同主办的第三届生物偶联药全球创新峰会(Global XDC 2024),将于9月10-12日在无锡重磅回归。大会涵盖2个主论坛+4个分论坛,预计参会企业300+家,参会专家100+位,参会观众1000+人。大会以“探索偶联药的无限可能”为主题,将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术,以及CMC挑战和商业化策略等内容,探索前沿技术进步、分享国际优秀生物科技公司的创新经验、引领ADC和XDC的新未来


本届峰会邀请了众多生物偶联药领域的国际专家与会,共同探讨创新合作,碰撞思想,助力生物偶联药行业蓬勃发展。



Global XDC 2024
国际阵容强势来袭
聆听偶联药的世界声音


3.png


Global XDC 2024
热门议题抢先一览
探索偶联药的无限可能

4.png

Keynote Speech

  • Rina-S-the missing link(er) 

  • Protein homeostasis by dual-precision targeted protein degradation and stabilization 

  • A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs 

  • MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression

  • NTX1105: development of a best-in-class ADC targeting Nectin-4 

  • Collaborating within the global life science ecosystem to advance breakthrough science

论坛一:Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

  • Next generation ADCs: novel targets, payloads, linkers and conjugation technologies

  • Nexatecan™: OHPAS-able Topo1 inhibitor for ADC

  • Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker,   and dual payload system

  • Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads

  • CS5001, a potential best-in-class ROR1 ADC

  • Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload

  • Polysorbates in biopharmaceuticals-approaches to mitigate risk

论坛二:Bioconjugates development beyond ADCs

  • RDC-the exploration of new drug modality in unmet clinical need

  • Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?

  • GBB’s AI-enabled ecosystem elevating biological drug development

  • Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies

  • Fully human common light chain technology for novel ADCs

论坛三:Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

  • Harnessing AbClick Pro® for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index

  • An overview on the new topoisomerases inhibitors technologies

  • Next generation ADCs:novel targets, payloads, linkers and conjugation technologies

  • Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

论坛四:CMC challenges and commercialization strategies

  • CMC scale-up challenges and COGs for site specific ADCs

  • Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment

  • The integrated analytical platform enables accelerated CMC development of XDCs

  • QbD considerations for ADC process

  • How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing

  • Non-clinical strategies for ADC drugs

更多确认嘉宾及议题持续公布中.....


主办单位


药明合联WuXi XDC、佰傲谷BioValley


时间地点


2024年9月10-12日(周二/周三/周四)

中国·无锡君来洲际酒店


报名方式



欢迎更多XDC研发企业加入!

点击我想参与即刻报名

标准通票:200元/人

温馨提示:如您收到主办方特别邀请,请通过特别邀请链接或者二维码进行注册登记,无需购买标准通票。

转发赢门票:转发本篇推文至朋友圈,集赞28个,即可获取标准通票一张(不含餐)。


联系我们


  • 定制参展/商务合作请联系:Stephen Sun 15966587556(微信同号)

  • 参会报名/媒体合作请联系:Abby Jiang 18217659261(微信同号)

6.png


特别感谢


7.png

8.png




头枕太湖,北依长江

9月无锡,温和飒爽

Global XDC 2024

期待您的莅临~

会议信息及议程,最终解释权归主办方,以实际安排为准
网友评论
评论0条,有0人参与,查看全部>>
最新评论
评论0条,有0人参与,查看全部>>